EP3765024A1 — Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
Assigned to Kandy Therapeutics Ltd · Expires 2021-01-20 · 5y expired
What this patent protects
The present invention generally relates to novel pharmaceutical formulations containing 2- [3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2- dimethylpropanamide, methods of…
USPTO Abstract
The present invention generally relates to novel pharmaceutical formulations containing 2- [3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2- dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.